Variety of suitable individuals: CDEC discussed the uncertainty in the quantity of individuals with moderately critical to serious hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical specialists consulted by CADTH indicated that some individuals who will be categorised as having gentle or reasonable illness could possibly have